A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The endpoint is to investigate if the addition of low molecular heparin - enoxaparin, will
result in a significant increase of overall survival in patients with small cell lung cancer,
receiving standard chemotherapy.